Document:

<PAGE>   1
                                                                   Exhibit 10.24

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                          SALES FORCE WORK ORDER # 8475

                 EFFECTIVE DATE OF WORK ORDER: OCTOBER 10, 2000

This Sales Force Work Order (the "Work Order") is entered into between The
Medicines Company ("TMC") and Innovex LP ("Innovex"), pursuant to the Master
Services Agreement, having an Effective Date of October 10, 2000, between TMC
and Innovex (the "Master Services Agreement"), and is subject to all the terms
and conditions set forth therein, except as may be otherwise expressly provided
herein. All capitalized terms used in this Work Order not otherwise defined
herein shall have the same definition as ascribed to that term in the Master
Services Agreement.

BRIEF DESCRIPTION OF SALES FORCE PROJECT:

Innovex is providing TMC with a field sales force of 52 Sales Representatives
and 2 Field Coordinators, together with the support of an Innovex National Sales
Director, a National Sales Manager and an Administrative Assistant, to support
TMC's sales and marketing efforts on TMC's pharmaceutical product AngiomaxTM.
This Work Order covers a two-year period as described below.

PROJECT TEAMS:

TMC CONTACT PERSON:  PAUL PUCCIONI
           ADDRESS:  5 SYLVAN WAY
                     PARSIPPANY, NJ 07054
             PHONE:  973-401-6460
               FAX:  973-656-9898

INNOVEX NATIONAL SALES MANAGER/NATIONAL SALES DIRECTOR:
                     BOB MCGOWAN/PHIL SALIMBENE
           ADDRESS:  10 WATERVIEW BLVD.
                     PARSIPPANY, NJ 07054
             PHONE:  973-257-4500
               FAX:  973-257-4581

Routine correspondence relevant to the operation of the sales force should be
sent to the above-named contact persons. All notices or similar communications
in regard to the terms or a change of terms of this Work Order are to be sent to
the parties named in the Master Services Agreement - Section 16. Notices.

                                       1
<PAGE>   2

PROJECT TERM AND KEY DATES:

Project Start Date                           October 16, 2000
Field Coordinator Start Date                 October 16, 2000
Sales Representative Start Date              December 11, 2000
Initial Live Training Dates                  January 4, 2001
Project End Date (Last Day Worked)           December 10, 2002

"Project Term" shall mean the period of time beginning on the Project Start Date
and ending on the Project End Date. Any renewal of the Project or extension of
the Project End Date shall be negotiated by the parties at least ninety (90)
days before the Project End Date, and shall be effective when agreed in writing.

DEFINITIONS

1.   "Day Worked" shall mean a day during which a Sales Representative details
     Customers, or attends scheduled company training and/or specifically
     designated home study. A "Day Worked" by a Field Coordinator shall mean a
     day during which the Field Coordinator performs duties and responsibilities
     described in the Work Order. Days Worked shall not include days on leave,
     holidays, sick days, vacations or any Saturday or Sunday, except for
     training or meeting days scheduled on a Saturday or Sunday. The average
     number of days worked in a twelve month period shall be two hundred
     thirty-two (232).

2.   "Detail" shall mean an interactive face-to-face contact by a Sales
     Representative with a Customer, during which a promotional message
     involving the Product is given in accordance with the Promotional Program.
     When used as a verb, "detail," "details" and "detailed" shall mean to
     engage in a Detail as defined herein.

3.   "Customer" shall mean physicians and other health care professionals
     legally authorized to write prescriptions for pharmaceutical products or
     otherwise have the ability to impact decisions to utilize TMC Product in
     "Target Accounts". This includes but is not limited to: Interventional
     Cardiologists, cath lab personnel, hospital pharmacists, P & T committee
     members and hospital administrators.

4.   "Product" shall mean the TMC pharmaceutical products specifically
     identified in this Work Order or any other product whose promotion and
     detailing is assigned to Innovex by mutual agreement with TMC.

5.   "Promotional Expense Budget" shall mean the funding and guidelines for use
     of such funding that are provided by TMC for use by the Sales Force when
     detailing Product.

6.   "Promotional Material" shall mean the Product labeling and package inserts,
     sales aids and detailing materials developed and provided by TMC, and other
     promotional support items provided by TMC to Innovex, for use in promotion
     of the Product.

                                       2
<PAGE>   3

7.   "Promotional Program" shall mean the marketing plan, strategy and
     promotional message for the Product, which will include use of the
     Promotional Material and the Promotional Expense Budget.

8.   "Sales Force" shall mean the Sales Representatives, Field Coordinators,
     National Sales Director, and National Sales Manager, individually and as a
     group, that have been assigned to deliver Details of the Product in
     accordance with the terms of this Agreement.

9.   "Sales Representative" shall mean an Innovex employee who has been trained
     and equipped to detail Customers.

10.  "Target Customer" shall mean one of the Customers specifically identified
     by TMC within a Sales Representative's territory to be detailed by the
     Sales Representative.

11.  "Target accounts" shall mean a specially identified account by TMC within a
     Sales Representative's territory to be detailed by the Sales
     Representative.

12.  "Territory" shall mean the United States and Puerto Rico. In connection
     with an individual Sales Representative, the territory shall be the
     geographic area assigned to the individual Sales Representative.

INNOVEX RESPONSIBILITIES AND OBLIGATIONS

1.   SALES FORCE. The Sales Force will be composed of the following Innovex
     employees:

              NUMBER                        POSITION TITLE
              ------                        --------------
                52         Sales Representatives
                 2         Field Coordinators
            1 (.1 FTE)     National Sales Director
            1 (.1 FTE)     National Sales Manager
            1 (.2 FTE)     Project Administrator (Administrative Assistant)

     TMC may request that Innovex provide additional Sales Representatives, by
     submitting a written request in substantially the form attached hereto as
     Exhibit 1, ("Additional Sales Representative Request Form"). As the total
     number of Sales Representatives increases for the Sales Force, additional
     Field Coordinators will also be increased in order to maintain a target
     ratio of Field Coordinators to Sales Representatives of approximately 1:27.

2.   RECRUITMENT. Innovex shall be responsible for recruitment and
     re-recruitment (replacement) of the Sales Representatives and Field
     Coordinators in accordance with the Sales Force Qualifications described
     below. Innovex shall be responsible for the cost of recruitment, background
     checks and drug screens. If TMC elects to participate in the final
     selection of members of the Sales Force, TMC shall approve or disapprove
     qualified candidates within five

                                       3
<PAGE>   4

     (5) business days after each qualified candidate is submitted to TMC for
     final selection. A "qualified candidate" must meet the Sales Force
     Qualifications. TMC shall be entitled to a recruitment rebate in the amount
     of for each Sales Representative or Field Coordinator hired by Innovex for
     the Sales Force who was referred to Innovex by TMC, prior to the tenth day
     of a territory vacancy; provided, however, that TMC shall not be eligible
     for a rebate in connection with any individual referred to Innovex by TMC
     who was already, at the time of the referral, included in the Innovex
     database as a candidate for employment, and Innovex can provide
     satisfactory evidence of such database inclusion. In addition, the rebate
     shall be reduced by the amount of actual expenses incurred by Innovex for
     recruitment and advertising for the territory, prior to the date of the TMC
     referral.

3.   SALES FORCE QUALIFICATIONS. Innovex will exercise best efforts to recruit
     from a diverse candidate base. A qualified candidate for Sales
     Representatives shall meet the following minimum qualifications: four-year
     college degree (B.A., B.S. or equivalent); 1-2 years hospital selling of
     pharmaceuticals (preferred) or devices to cardiologists/cath labs/ERs. A
     qualified candidate for Field Coordinator shall meet the following minimum
     qualifications: four-year college degree (B.A., B.S. or equivalent); 2
     years pharmaceutical sales experience, 2 years management experience. The
     three Salary Tiers for TMC Representatives and the criteria they must
     satisfy are provided in the Angiomax Representative Profile, attached to
     this Work Order.

4.   POSITION DESCRIPTIONS AND DUTIES.Innovex shall manage, supervise and
     evaluate the performance of the National Sales Manager, National Sales
     Director, Field Coordinators and Sales Representatives in accordance with
     the responsibilities and duties identified below. All Sales Force employees
     shall demonstrate the following: work ethic and integrity; planning,
     organizing and territory management skills; strong interpersonal skills;
     excellent communication skills; critical thinking and analysis; problem
     solving; decisiveness; sound judgment; customer-focused selling skills;
     basic computer skills; ability to listen and learn.

     SALES REPRESENTATIVES
          -    Generate sales within an assigned territory
          -    Maintain and update current and prospective target physician
               profiles
          -    Keep current with market knowledge and competitive
               products
          -    Maintain a professional image for TMC and TMC Products
          -    Participate in all training and sales meetings
          -    Plan and organize territory to meet sales and call targets
          -    Make sales presentations (details) - individual, one-on-one,
               in-services
          -    Comply with PDMA
          -    Make complete, accurate and timely submission of all
               time-keeping, call activity and expense reports
          -    Compliance with Promotional Program, and proper use of
               Promotional Materials and Promotional Expense Budgets

                                       4
<PAGE>   5

     NATIONAL SALES MANAGER/NATIONAL SALES DIRECTOR

          -    Recruit, interview and select Field Coordinators
          -    Handle periodic performance review, personnel issues, discipline
               and termination of Field Coordinators
          -    Communicate with TMC field/regional managers on regular and
               timely basis
          -    Assist with the planning and delivery of training, and periodic
               sales meetings
          -    Review and approve expense reports; monitor compliance with
               expense policies.
          -    Monitors compliance with Promotional Program, and proper use of
               Promotional Materials and Promotional Expense Budgets
          -    Monitors compliance with PDMA

     FIELD COORDINATORS

          -    Assist with recruitment of Sales Representatives
          -    Handle periodic performance review, personnel issues, discipline
               and termination of Sales Representatives
          -    Review and approve expense reports; monitor compliance with
               expense policies
          -    Conduct field visits with Sales Representatives as schedule
               permits in order to: assess and monitor field activity and work
               schedules; to monitor and manage field reporting, including call
               reporting; to implement performance or disciplinary plans.
          -    Communicate with TMC field/regional managers on regular and
               timely basis
          -    Assist with the planning and delivery of training, and periodic
               sales meetings, if necessary

5.   SALES FORCE COMPENSATION; BENEFITS. Innovex shall compensate the Sales
     Force employees with a combination of salary and variable incentive
     (bonus). Innovex and TMC, shall mutually establish a target average salary
     and salary matrix, which recognizes greater experience and training, and
     preferred selection criteria notwithstanding section 5.4 of the Master
     Agreement. The terms and conditions of a variable incentive compensation
     plan ("Incentive Plan") shall be mutually determined by Innovex and TMC,
     including eligibility criteria and performance targets. The Incentive Plan
     may also include incentive awards such as trips and prizes. Innovex shall
     administer the Incentive Plan, determine eligibility and pay the incentive
     compensation and awards, in accordance with the Incentive Plan provided no
     payments are made under the Incentative Plan without the prior written
     consent of TMC. Sales Force employees shall be eligible to receive an auto
     allowance, and shall be entitled to participate in the Innovex employee
     benefit plans for health and dental care, 401K, employee stock purchase and
     stock ownership plans, in accordance with company eligibility criteria.

6.   TRAINING AND PERIODIC SALES MEETINGS. Innovex shall assist TMC with
     organizing and delivering initial training of the Sales Force, backfill
     training of replacement Field Coordinators and Sales Representatives and
     all follow-up training, including periodic sales meetings.

7.   PROMOTIONAL ACTIVITIES. Innovex shall be responsible for managing and
     monitoring the promotional activities of the Sales Force, in strict
     adherence to the Promotional Program and using only the Promotional
     Materials provided by TMC. Sales Representatives shall not be

                                       5
<PAGE>   6

     permitted to develop, create or use any other promotional material or
     literature in connection with the promotion of the Product. Sales
     Representatives will be required to immediately cease the use of any
     Promotional Materials when Innovex is instructed to do so by TMC. Innovex
     shall monitor that Promotional Materials are not changed, (including,
     without limitation, by underlining or otherwise highlighting any text or
     graphics or adding any notes thereto) by the Sales Representatives. Sales
     Representatives shall be required to limit their statements and claims
     regarding the Product, including as to efficacy and safety, to those which
     are consistent with the Product labels, package inserts and Promotional
     Materials. The Sales Representatives shall not be permitted to add, delete
     or modify claims of the efficacy or safety in the promotion of the Product,
     nor shall the Sales Representatives be permitted to make any untrue or
     misleading statements or comments about the Products or any TMC competitors
     or competitor products.

8.   PROJECT REPORTS. Innovex shall provide TMC a monthly Project report, which
     shall include: (i) headcount, reported nationally, by region/district;
     vacancy rates, turnover, personnel transfers to TMC, status of
     recruitment/hiring; (ii) Project status, milestones, and progress toward
     achieving objectives; (iii) financial accountability, tracking expenses
     against budget; and (iv) call reporting, as contemplated by item 9 below.

9.   REPORTING BY SALES REPRESENTATIVES. Sales Representatives shall be required
     to report all field activities and expenditures in a manner that is timely,
     accurate and honest, and in accordance with policies and procedures for the
     applicable reporting systems. Innovex Field Coordinators shall routinely
     reinforce the importance of compliance with the reporting guidelines and
     policies (e.g. call reporting, promotional budget expenditures, travel
     expenses). Newly hired Sales Representatives shall receive training on the
     reporting systems, guidelines and policies during the initial sales
     training program.

10.  ITMS AND CALL REPORTING. Innovex shall provide the Innovex Territory
     Management System, including automated call reporting. Innovex shall equip
     the Sales Force with computer hardware and software, including a
     combination printer/fax/copier, and shall bear the cost of database and
     system administration, licenses, access to data/replication lines, help
     desk support, and training of the Sales Force in proper use of the
     computers and software. Sales Representatives shall not distribute samples
     of TMC products and Innovex shall have no responsibility for sample
     accountability.

11.  CELL PHONES. Innovex shall provide cell phones for the Sales
     Representatives.

CUSTOMER RESPONSIBILITIES AND OBLIGATIONS

1.   PROMOTIONAL PROGRAM AND PROMOTIONAL MATERIALS. TMC shall be responsible for
     providing a Promotional Program, Promotional Materials and Promotional
     Expense Budget that (i) will not involve the counseling or promotion of a
     business arrangement that violates federal or state law; (ii) will be in
     compliance with the AMA Guidelines on Gifts to Physicians from Industry;
     and (iii) shall not require or encourage the Sales Representatives to
     offer, pay, solicit

                                       6
<PAGE>   7

     or receive any remuneration from or to Prescribers to induce referrals or
     purchase of TMC Product. TMC shall be responsible for providing written
     guidelines for proper use of the TMC's Promotional Expense Budget.

2.   TRAINING AND PERIODIC SALES MEETINGS.
     TMC shall be responsible for the following:

     -    Programming and materials for initial Sales Force training of 7-9 days
          duration. The initial training agenda shall include 8 hours designated
          for Innovex training regarding personnel management, compensation and
          benefits and field administration.

     -    Programming, materials and facilities for periodic sales meetings of
          2-3 days duration or otherwise as agreed by the parties.

2.   PDMA. TMC and Innovex shall cooperate in connection with PDMA compliance
     investigations and audits. TMC will provide to Innovex for review and
     comment, a copy of any PDMA compliance report in connection with the Sales
     Force, prior to filing with the FDA.

3.   SALES DATA. TMC shall be solely responsible for obtaining historic and
     ongoing sales data regarding TMC Products.

4.   BUSINESS CARDS; PORTFOLIOS. Innovex shall supply the Sales Force with
     business cards, the content of which shall be subject to approval by TMC,
     such approval not to be unreasonably withheld. Innovex shall supply the
     Sales Force with detail portfolios.

5.   SALES FORCE TRAVEL EXPENSES. TMC shall be responsible for the following
     Sales Force travel, lodging and meal expenses, when necessary and actually
     incurred by the Sales Force (in the amounts authorized in a mutually agreed
     Sales Force travel expense budget):

     -    Travel expenses of Sales Force in connection with all training and
          periodic sales meetings

     -    Travel expenses for Field Coordinators and National Sales Manager in
          connection with field management in the territories.

6.   SALES & MARKETING SUPPORT. TMC-employed Regional Managers shall provide
     sales and marketing support and direction to the Sales Representatives. TMC
     Regional Managers shall not be involved with the discipline and work
     evaluations of the Sales Force except in an advisory capacity.

FEES AND PASS-THROUGH EXPENSES

1.   a. PASS-THROUGH EXPENSES. "Pass-Through Expenses" shall mean the reasonable
     and necessary out-of-pocket costs and expenses actually incurred by Innovex
     in providing Services, in accordance with a mutually agreed written budget
     or the express terms of the Work Order.

                                       7
<PAGE>   8

   CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     b. DAILY FEES. TMC shall pay Innovex a Daily Fee for each Day Worked by
     Sales Representatives and Field Managers during the Project Term. The Daily
     Fees and total estimated Daily Fees during the Project Term are stated in
     the following tables:

YEAR ONE (10/16/2000 TO 12/10/2001)

<TABLE>
<CAPTION>

                                                            ESTIMATED      ESTIMATED
                                                           DAYS WORKED    TOTAL DAYS    ESTIMATED
SALES FORCE POSITIONS           NUMBER      DAILY RATE        WORKED        WORKED      TOTAL FEES
---------------------           ------      ----------     -----------    ----------    ----------
<S>                         <C>          <C>           <C>            <C>           <C>

Sales Representatives             52          $[**]            232          12,064       $ [**]
---------------------------------------------------------------------------------------------------
Field Coordinators                 2          $[**]            251             502       $ [**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Director (.1 FTE)      1                                                       [**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Manager (.1 FTE)       1                                                       [**]
---------------------------------------------------------------------------------------------------
Project Admin. (.2 FTE)            1                                                       [**]
---------------------------------------------------------------------------------------------------
                                                              ESTIMATED TOTAL FEES       $6,488,120
---------------------------------------------------------------------------------------------------
</TABLE>

YEAR TWO (12/11/2001 TO 12/10/2002)

<TABLE>
<CAPTION>

                                                            ESTIMATED      ESTIMATED
                                                           DAYS WORKED    TOTAL DAYS    ESTIMATED
SALES FORCE POSITIONS           NUMBER      DAILY RATE        WORKED        WORKED      TOTAL FEES
---------------------           ------      ----------     -----------    ----------    ----------
<S>                         <C>          <C>           <C>            <C>           <C>

Sales Representatives             52          $[**]            232         12,064         $[**]
---------------------------------------------------------------------------------------------------
Field Coordinators                 2          $[**]            232            464         $[**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Director (.1 FTE)      1                                                       [**]
---------------------------------------------------------------------------------------------------
Nat'l Sales Manager (.1 FTE)       1                                                       [**]
---------------------------------------------------------------------------------------------------
Project Admin. (.2 FTE)            1                                                       [**]
---------------------------------------------------------------------------------------------------
                                                              ESTIMATED TOTAL FEES       $6,440,320
---------------------------------------------------------------------------------------------------
</TABLE>

2.   TAKE-ON FEE. Innovex shall charge TMC a fee for each Sales Representative
     or Field Coordinator that becomes employed by TMC or a TMC Affiliate during
     the first 12 months of such employee's provision of services to TMC under
     the terms of this Work Order. The fee shall be equal to [**] percent
     ([**]%) of the employee's then current Innovex annual salary if the
     employee is taken on during the first six months of such provision of
     services and [**] percent ([**]%) during the next six months. The fee shall
     be due and payable upon the employee's commencement of employment with TMC.
     There shall be no take-on fee for any Sales Representative or Field
     Coordinator that becomes employed by TMC or a TMC Affiliate after such
     employee has provided twelve months of services under the terms of this
     Work Order. In addition, if the turnover rate exceeds [**] percent ([**]%)
     during Year One of the Project Term (i.e. turnover of [**] more territories
     between 10/16/2000 and 12/10/2001, TMC shall have the option to rollover
     and employ the entire Sales Force without obligation to pay any take-on fee
     in connection with such rollover; provided, however, the exercise of this
     option by TMC shall not shorten the termination notice provisions of
     Section 11 of the Master Agreement. The calculation of turnoiver shall
     exclude

                                       8
<PAGE>   9

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     (i) any Sales Representative that is hired by TMC or a TMC Affiliate; and
     (ii) any Sales Representative that is terminated or removed from the Sales
     Force at the request of TMC.

3.   INCENTIVE PLAN ADMINISTRATION. TMC shall pay Innovex an amount equal to (i)
     the amount of all incentive compensation earned by Sales Representatives
     and Field Coordinators in accordance with the terms of the Incentive Plan;
     and (ii) an amount equal to [**]% of the incentive compensation for
     Innovex's employer costs (payroll taxes).

4.   PAYMENT SCHEDULE. Innovex shall invoice TMC monthly for all Daily Fees,
     Take-on Fees and Pass-Through Expenses. At the end of each calendar month
     Innovex shall provide TMC a list of the billable Sales Force personnel and
     the total number of Days Worked multiplied by the respective Daily Fee
     rate. Innovex shall invoice TMC in advance for all incentive compensation
     and related employer costs, and the incentive compensation shall be paid to
     the Innovex Personnel by Innovex only after TMC pays to Innovex the amount
     of the applicable incentive compensation invoices.

5.   RECOVERY OF COSTS UPON EARLY TERMINATION. If TMC terminates this Work Order
     before December 10, 2001, then in addition to all Fees and Pass-through
     Expenses that are payable in accordance with Section 11.5 of the Master
     Services Agreement, TMC shall also pay to Innovex (a) any non-cancelable
     obligations incurred in accordance with the terms of this Work Order, net
     of recoveries (e.g. cancellation fees, computer lease termination fees);
     and (b) the amount of $[**] for each month remaining (prorated for partial
     months) prior to December 10, 2001 (at the conclusion of the contractual
     notice period), to compensate Innovex for unamortized costs of recruitment,
     training, and ITMS start-up.

6.   Fee Deposit. In accordance with the terms of the Letter of Intent, TMC has
     paid Innovex the amount of $[**] on October 16, 2000, and TMC shall pay an
     additional sum of $[**] on or before December 31, 2000. This amount shall
     continue to be held by Innovex and will be credited towards the invoices
     for Fees and Pass-Through Expenses for the final two months of the Project
     Term and upon the early termination of this Work Order.

7.   EXPENSE ALLOCATION CHART. The financial responsibility of Innovex and TMC
     for expenses and costs of Sales Force operation shall be allocated in
     accordance with the terms of this Work Order, which are summarized for
     illustrative purposes in the "Sales Force Expense Allocation" chart
     (Attachment A).

                                       9
<PAGE>   10
            Confidential Materials omitted and filed separately with
      the Securities and Exchange Commission. Asterisks denote omissions.

SPECIAL TERMS

1.   Notwithstanding anything in this Work Order or the Master Services
     Agreement to the contrary, TMC shall not be allowed to terminate this Work
     Order or the Master Services Agreement on earlier than 90 days notice due
     to any delay or failure of AngiomaxTM to be approved by the FDA.

2.   The Daily Fees recited above are conditioned upon Innovex paying the
     following average annual salaries, using a combination of the three Salary
     Tiers as outlined in the Angiomax Representative Profile (Attachment B):

                                     PER REP.                 PER F.C.
                                     --------                 --------
     Projected Salaries          $[**] in Year One        $[**] in Year One
     ----------------------------------------------------------------------
                                 $[**] in Year Two        $[**] in Year Two

     Beginning with the monthly invoice for December 2000 (to be prepared in
     January 2001), Innovex will calculate the average annual salary actually to
     be paid to Sales Representatives and Field Coordinators during Year One,
     and shall make an appropriate adjustment to the Daily Fees, provided,
     however, the average annual salary per Sales Representative does not exceed
     $[**] in Year One or $[**] in Year Two. At the end of March 2001 and
     quarterly thereafter, Innovex will reconcile its actual average annual
     salary against the projected salary, above, and make an appropriate
     adjustment to the Daily Fees.

3.   Innovex shall be entitled to earn in connection with the sales and
     marketing services provided pursuant to this Work Order up to $[**] in
     incentive compensation based on the percentage of sales achieved over a Net
     Sales Target as described in Chart II below. The applicable Net Sales
     Target shall be as agreed by the parties in good faith. Should the parties
     fail to agree on an applicable Net Sales Target for either Year One or Year
     Two prior to the time Sales Representatives begin detailing Customers
     during that year, then Innovex's incentive compensation for that year shall
     be $[**] (without regard to whether or not actual sales meet or exceed a
     sales target). The incentive compensation shall be payable to Innovex on or
     before 3/1/2002. Year Two incentive compensation shall be payable to
     Innovex on or before 3/1/2003. In the event the Agreement is terminated
     during Year One or Year Two, the applicable Net Sales Target and incentive
     compensation due for that year shall be prorated as outlined in the example
     contained in Chart I below.

                                       10
<PAGE>   11

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

     CHART I
     EXAMPLE INCENTIVE: EARLY TERMINATION

     Termination Date                                           10/1/01
     ---------------------------------------------------------------------------
     Innovex Field Time in 2001                       9 months (1/4/01- 9/30/01)
     ---------------------------------------------------------------------------
     Proration Factor                                    0.75 (9 of 12 months)
     ---------------------------------------------------------------------------
     2001 Net Sales Target                                       $[**]
     ---------------------------------------------------------------------------
     2001 Net Sales Actual                                       $[**]
     ---------------------------------------------------------------------------
     % of Sales Target                                            116%
     ---------------------------------------------------------------------------
     Payout Schedule                                             $[**]
     ---------------------------------------------------------------------------
     Payment due Innovex                                     $[**] x 0.75)
     ---------------------------------------------------------------------------

     CHART II

     % of  Sales v.  Net        Incentive Compensation Payable to Innovex
     Sales Target               for Actual Sales vs. Target
     ---------------------------------------------------------------------------
                                                           Total Amount Payable
     ---------------------------------------------------------------------------
      100% (target)                 $0                     $0
     ---------------------------------------------------------------------------
      102%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      104%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      106%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      108%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      110%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      112%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      114%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      116%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      118%                          $[**]                  $[**]
     ---------------------------------------------------------------------------
      120%+                         $[**]                  $[**]
     ---------------------------------------------------------------------------

                                       11

<PAGE>   12

In Witness Whereof, TMC and Innovex have caused this Work Order # 8475 to be
duly executed on their behalf by their authorized representatives and made
effective as of Effective Date of Work Order appearing above.

ACCEPTED AND AGREED TO BY:

THE MEDICINES COMPANY               INNOVEX LP
                                    By: Innovex America Holding
                                        Company, its General Partner

/s/ Thomas P. Quinn                 s/s John E. Monahan
----------------------------        -----------------------------
By:    Thomas P. Quinn              By:    John E. Monahan
Title: VP Sales and Marketing       Title: President
Date:  November 17, 2000            Date:  November 17, 2000

                                       12

<PAGE>   13

                     ATTACHMENT A TO SALES FORCE WORK ORDER
                         SALES FORCE EXPENSE ALLOCATION
                                  OCTOBER, 2000
                                 PROJECT # 8475

<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------------------------------
                                                                             INNOVEX                              TMC
                                                                             DIRECT         PASS-THROUGH         DIRECT
                          CATEGORY                                          EXPENSES          EXPENSES          EXPENSES
------------------------------------------------------------------------------------------------------------------------
<S>                                                                      <C>            <C>                <C>

Salary, including payroll taxes, for Sales Representatives, Field               X
Coordinators, National Sales Manager
------------------------------------------------------------------------------------------------------------------------
Incentive compensation (bonus) for Sales Representatives & Field                                  X
Coordinators, including payroll taxes
------------------------------------------------------------------------------------------------------------------------
Benefits package, including (401k), ESOP, ESPP, medical, dental, Rx,            X
vacation, holidays
------------------------------------------------------------------------------------------------------------------------
Auto Costs, including monthly allowance, mileage reimbursement, parking and     X
tolls.
------------------------------------------------------------------------------------------------------------------------
Basic Business Expenses, including phone, paper supplies, postage and voice     X
mail.
------------------------------------------------------------------------------------------------------------------------
Business Cards & Portfolio; Cell Phones                                         X
------------------------------------------------------------------------------------------------------------------------
Call Reporting; ITMS                                                            X
------------------------------------------------------------------------------------------------------------------------
Computers for Sales Force Representatives, including software,                  X
helpdesk support, data/replication lines; combo fax/printer/copier
------------------------------------------------------------------------------------------------------------------------
Infrastructure support (operations, HR, finance, legal)                         X
------------------------------------------------------------------------------------------------------------------------
Liability Insurance: employment, workers comp, E & O, CGL, auto                 X
------------------------------------------------------------------------------------------------------------------------
Recruitment and re-recruitment, includes drug screens, background and           X
motor vehicle checks
------------------------------------------------------------------------------------------------------------------------
Meetings:  TMC national, regional and district meetings; product                                                   X
launches
------------------------------------------------------------------------------------------------------------------------
Promotional Expense Budget (access money)                                                         X
------------------------------------------------------------------------------------------------------------------------
Promotional Program and Promotional Materials (sales aids)                                                         X
------------------------------------------------------------------------------------------------------------------------
Promotional marketing expenses, including sales data                                                               X
------------------------------------------------------------------------------------------------------------------------
Training program, materials and facilities; initial and follow-up                                                  X
------------------------------------------------------------------------------------------------------------------------
Travel Expenses (air, hotel & meals) for Sales Reps, Field
Coordinators, National Sales Manager, National Sales Director for:
*Interviewing                                                                   X
*Training                                                                                         X
*Territory travel for field management purposes                                                   X
------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       13

<PAGE>   14

                       EXHIBIT 1 TO SALES FORCE WORK ORDER
                  ADDITIONAL SALES REPRESENTATIVE REQUEST FORM

This Request for Additional Sales Representative is issued pursuant to the
Master Services Agreement between TMC and Innovex, dated October 10, 2000 and
Work Order # 8475, dated October 10, 2000. (Sales Force # 8475).

--------------------------------------------------------------------------------
PART 1                                 To be completed by TMC
                                       Attach any relevant, helpful information
--------------------------------------------------------------------------------
NUMBER OF SALES REPRESENTATIVES
REQUESTED
--------------------------------------------------------------------------------

TERRITORY LOCATION(S)
--------------------------------------------------------------------------------

REQUESTED START DATE
--------------------------------------------------------------------------------

AUTHORIZED CUSTOMER REPRESENTATIVE     Signature: ___________________________
SUBMITTING REQUEST                     Name:
                                       Title:
                                       Date:
                                       Phone:
                                       Fax:

--------------------------------------------------------------------------------
PART 2                                 TO BE COMPLETED BY INNOVEX
                                       INNOVEX SHALL RESPOND WITHIN TEN (10)
                                       BUSINESS DAYS AFTER RECEIPT OF THE
                                       ADDITIONAL SALES REPRESENTATIVES REQUEST.
--------------------------------------------------------------------------------

This Additional Sales Representative   Request is Accepted, and Recruitment
Request Form was Received by Innovex   shall begin immediately:
on the following date:                 ______________________________________
                                       (sign and date)
         _____________________         Contact Person:
                                       Phone:
--------------------------------------------------------------------------------

                                       REQUEST IS NOT ACCEPTED (identify above
                                       information which must be clarified or
                                       changed before Request may be accepted
                                       by Innovex):

                                       _______________________________________
                                       (sign and date)
                                       Contact Person:
                                       Phone:
--------------------------------------------------------------------------------

                                       14

<PAGE>   15

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                   ATTACHMENT B TO THE SALES FORCE WORK ORDER
                                    ANGIOMAX
                             REPRESENTATIVE PROFILE

Tier 1 Candidate   ($[**] - $ [**])
   -  3 - 5yrs. pharmaceutical sales experience
   -  2 years hospital sales experience
   -  2+ years cardiovascular background
   -  Sold Cath Lab drugs
      -  GP IIb/IIIa inhibitors
      -  Plavix
      -  Ticlid
      -  Thrombolytics
         -  Activase
         -  Retavase
         -  Streptase
         -  Eminase
         -  Abbokinase (best chance)
      -  LMWH
         -  Lovenox
         -  Fragmin
         -  Normiflo
         -  Orgaran
   -  Or sold Cath Lab devices
         -  Catheters
         -  Stents
         -  Sheaths
         -  Commodity cath lab sales
         -  Etc.
   -  Cath Lab contacts via other cardiology hospital-based pharmaceutical sales
         -  Pfizer/Parke Davis
         -  BMS
         -  Etc.
   -  Proven sales track record - sales awards and sales contest winners

TIER 2 CANDIDATE ($[**] - $ [**])
   -  2 - 3yrs. pharmaceutical sales experience
   -  Cardiovascular experience preferred
   -  Smaller pharma. cardiovascular hospital representatives
   -  Big pharma. cardiovascular field representatives
      -  Statins
      -  Aces
      -  AII's
      -  CCB's
      -  Antihypertensives
   -  Contrast imaging sales representatives

                                       15

<PAGE>   16

  CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
                EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

-  Hospital based personnel with cardiovascular background
   -  Pharmacists
   -  CCU nurses
   -  Cath lab nurses
   -  Cath Lab techs

 TIER 3 CANDIDATE ($[**] - $ [**])

-  Top-notch sales people that want to break into the industry
-  Nurses

                                       16<PAGE>   1
                                                                    Exhibit 10.1

                     CHARLES RIVER ASSOCIATES INCORPORATED

               1998 INCENTIVE AND NONQUALIFIED STOCK OPTION PLAN

SECTION 1. PURPOSE

     This 1998 Incentive and Nonqualified Stock Option Plan (the "Plan") of
Charles River Associates Incorporated (the "Company"), is designed to provide
additional incentive to executives and other key employees of the Company, and
any parent or subsidiary of the Company, and to certain other individuals
providing services to or acting as directors of the Company or any such parent
or subsidiary. The Company intends that this purpose will be effected by the
granting of incentive stock options ("Incentive Stock Options") as defined in
Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), and
nonqualified stock options ("Nonqualified Options") under the Plan which afford
such executives, key employees or other individuals an opportunity to acquire or
increase their proprietary interest in the Company through the acquisition of
shares of its Common Stock. The Company intends that Incentive Stock Options
issued under the Plan will qualify as "incentive stock options" as defined in
Section 422 of the Code and the terms of the Plan shall be interpreted in
accordance with this intention. As used in the Plan the terms "parent" and
"subsidiary" shall have the respective meanings set forth in Section 424 of the
Code.

SECTION 2. ADMINISTRATION

     2.1 The Plan Administrator.  The Plan shall be administered by the Plan
Administrator (the "Plan Administrator"), which shall consist of the Board of
Directors of the Company (the "Board") or, if appointed by the Board, a
committee consisting of at least two "Disinterested Directors." As used herein,
the term Disinterested Director means any director of the Company who (i) is not
a current employee of the Company or a member of an "affiliated group," as such
term is defined in Section 1504(a) of the Code, which includes the Company (an
"Affiliate"), (ii) is not a former employee of the Company or any Affiliate who
receives compensation for prior services (other than benefits under a
tax-qualified retirement plan) during the Company's or any Affiliate's taxable
year (iii) has not been an officer of the Company or any Affiliate; and (iv)
does not receive remuneration from the Company or any Affiliate, either directly
or indirectly, in any capacity other than as a director. If the Plan is not
administered by the Board, none of the members of the Plan Administrator shall
be an officer or other employee of the Company. It is the intention of the
Company that the Plan, if not administered by the Board, shall be administered
by a committee having two or more "Non-Employee Directors" within the meaning of
Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the "1934
Act"), but the authority and validity of any act taken or not taken by the Plan
Administrator shall not be affected if any person administering the Plan is not
a Non-Employee Director. Except as specifically reserved to the Board under the
terms of the Plan, the Plan Administrator shall have full and final authority to
operate, manage and administer the Plan on behalf of the Company. Action by the
Plan Administrator shall require the affirmative vote of a majority of all
members thereof.

     2.2 Powers of the Plan Administrator.  Subject to the terms and conditions
of the Plan, the Plan Administrator shall have the power:

          (a) To determine from time to time the persons eligible to receive
     options and the options to be granted to such persons under the Plan and to
     prescribe the terms, conditions, restrictions, if any, and provisions
     (which need not be identical) of each option granted under the Plan to such
     persons;

          (b) To construe and interpret the Plan and options granted thereunder
     and to establish, amend, and revoke rules and regulations for
     administration of the Plan. In this connection, the Plan Administrator may
     correct any defect or supply any omission, or reconcile any inconsistency
     in the Plan, or in any option agreement, in the manner and to the extent it
     shall deem necessary or

<PAGE>   2

     expedient to make the Plan fully effective. All decisions and
     determinations by the Plan Administrator in the exercise of this power
     shall be final and binding upon the Company and optionees;

          (c) To make, in its sole discretion, changes to any outstanding option
     granted under the Plan, including: (i) to reduce the exercise price, (ii)
     to accelerate the vesting schedule or (iii) to extend the expiration date;
     and

          (d) Generally, to exercise such powers and to perform such acts as are
     deemed necessary or expedient to promote the best interests of the Company
     with respect to the Plan.

SECTION 3. STOCK

     3.1 Stock to be Issued.  The stock subject to the options granted under the
Plan shall be shares of the Company's authorized but unissued common stock,
without par value (the "Common Stock"), or shares of the Company's Common Stock
held in treasury. The total number of shares that may be issued pursuant to
options granted under the Plan shall not exceed an aggregate of 1,870,000 shares
of Common Stock; provided, however, that the class and aggregate number of
shares which may be subject to options granted under the Plan shall be subject
to adjustment as provided in Section 8 hereof.

     3.2 Expiration, Cancellation or Termination of Option.  Whenever any
outstanding option under the Plan expires, is cancelled or is otherwise
terminated (other than by exercise), the shares of Common Stock allocable to the
unexercised portion of such option may again be the subject of options under the
Plan.

     3.3 Limitation on Grants.  In no event may any Plan participant be granted
options with respect to more than 150,000 shares of Common Stock in any calendar
year. The number of shares of Common Stock issuable pursuant to an option
granted to a Plan participant in a calendar year that is subsequently forfeited,
cancelled or otherwise terminated shall continue to count toward the foregoing
limitation in such calendar year. In addition, if the exercise price of an
option is subsequently reduced, the transaction shall be deemed a cancellation
of the original option and the grant of a new one so that both transactions
shall count toward the maximum shares issuable in the calendar year of each
respective transaction.

SECTION 4. ELIGIBILITY

     4.1 Persons Eligible.  Incentive Stock Options under the Plan may be
granted only to officers and other employees of the Company or any parent or
subsidiary of the Company. Nonqualified Options may be granted to officers or
other employees of the Company or any parent or subsidiary of the Company, and
to members of the Board and consultants or other persons who render services to
the Company or any such parent or subsidiary (regardless of whether they are
also employees), provided, however, that options may be granted to members of
the Board who are neither employees of the Company or any such parent or
subsidiary nor consultants who provide economic consulting services to or in
conjunction with the Company or any such parent or subsidiary ("Outside
Directors") only as provided in Section 4.4.

     4.2 Greater-Than-Ten-Percent Stockholders.  Except as may otherwise be
permitted by the Code or other applicable law or regulation, no Incentive Stock
Option shall be granted to an individual who, at the time the option is granted,
owns (including ownership attributed pursuant to Section 424(d) of the Code)
more than ten percent of the total combined voting power of all classes of stock
of the Company or any parent or subsidiary (a "greater-than-ten-percent
stockholder"), unless such Incentive Stock Option provides that (i) the purchase
price per share shall not be less than one hundred ten percent of the fair
market value of the Common Stock at the time such option is granted, and (ii)
that such option shall not be exercisable to any extent after the expiration of
five years from the date it is granted.

     4.3 Maximum Aggregate Fair Market Value.  The aggregate fair market value
(determined at the time the option is granted) of the Common Stock with respect
to which Incentive Stock Options are exercisable for the first time by any
optionee during any calendar year (under the Plan and any other plans of the
Company or any parent or subsidiary for the issuance of incentive stock options)
shall not exceed $100,000 (or such greater amount as may from time to time be
permitted with respect to incentive stock

<PAGE>   3

options by the Code or any other applicable law or regulation). Any option
granted in excess of the foregoing limitation shall be specifically designated
as being a Nonqualified Option.

     4.4 Option Grants to Outside Directors.

          (a) Grant of Options Upon Election to Board.  Each Outside Director
     joining the Board at or subsequent to the meeting of the Company's
     stockholders at which the Plan is approved (the "Approval Meeting") shall
     automatically be granted, upon such Outside Director so joining the Board,
     an initial Nonqualified Option to purchase 10,000 shares of Common Stock.
     Such Nonqualified Option shall vest and become exercisable in three equal
     annual installments cumulatively beginning on the first anniversary of the
     date of grant.

          (b) Grant of Options Upon Re-Election to Board or Continuation on the
     Board.  Each Outside Director who shall be re-elected by the stockholders
     of the Company to the Board at or subsequent to the Approval Meeting shall
     automatically be granted, immediately following the meeting of stockholders
     at which such Outside Director shall be re-elected, a Nonqualified Option
     to purchase 5,000 shares of Common Stock. In addition, each Outside
     Director whose term of office shall not expire at any annual meeting of
     stockholders or special meeting in lieu thereof subsequent to the Approval
     Meeting and who shall remain an Outside Director after such meeting shall
     automatically be granted, immediately following such meeting, a
     Nonqualified Option to purchase 5,000 shares of Common Stock. Each
     Nonqualified Option described in this Section 4.4(b) shall vest and become
     exercisable in full on the first anniversary of the date of grant.

          (c) Purchase Price.  The purchase price per share of Common Stock
     under each Nonqualified Option granted pursuant to this Section 4.4 shall
     be equal to the fair market value of the Common Stock on the date the
     Nonqualified Option is granted, such fair market value to be determined in
     accordance with the provisions of Section 6.3.

          (d) Expiration.  Each Nonqualified Option granted to an Outside
     Director under this Section 4.4 shall expire on the fifth anniversary of
     the date of grant with respect to all Nonqualified Options so granted prior
     to the date of the approval of this Plan by the Company's stockholders in
     1999 and the tenth anniversary of the date of grant with respect to all
     other Nonqualified Options so granted.

SECTION 5. TERMINATION OF EMPLOYMENT OR DEATH OF OPTIONEE

     5.1 Termination of Employment.  Except as may be otherwise expressly
provided herein, options shall terminate on the earlier of:

          (a) the date of expiration thereof; or

          (b) immediately upon the termination of the optionee's employment with
     or performance of services for the Company (or any parent or subsidiary of
     the Company) by the Company (or any such parent or subsidiary) for cause
     (as determined by the Company or such parent or subsidiary), without cause
     or voluntarily by the optionee;

provided, however, that Nonqualified Options granted to persons who are not
employees of the Company (or any parent or subsidiary of the Company) need not,
unless the Plan Administrator determines otherwise, be subject to the provisions
set forth in clause (b) above.

     An employment relationship between the Company (or any parent or subsidiary
of the Company) and the optionee shall be deemed to exist during any period in
which the optionee is employed by the Company (or any such parent or
subsidiary). Whether authorized leave of absence, or absence on military or
government service, shall constitute termination of the employment relationship
between the Company (or any parent or subsidiary of the Company) and the
optionee shall be determined by the Plan Administrator at the time thereof.

     As used herein, "cause" shall mean (x) any material breach by the optionee
of any agreement to which the optionee and the Company (or any parent or
subsidiary of the Company) are both parties,

<PAGE>   4

(y) any act or omission to act by the optionee which may have a material and
adverse effect on the business of the Company (or any such parent or subsidiary)
or on the optionee's ability to perform services for the Company (or any such
parent or subsidiary), including, without limitation, the commission of any
crime (other than ordinary traffic violations), or (z) any material misconduct
or material neglect of duties by the optionee in connection with the business or
affairs of the Company (or any such parent or subsidiary) or any affiliate of
the Company (or any such parent or subsidiary).

     5.2 Death or Retirement of Optionee.  In the event of the death of the
holder of an option that is subject to clause (b) of Section 5.1 above prior to
termination of the optionee's employment with or performance of services for the
Company (or any parent or subsidiary of the Company) and before the date of
expiration of such option, such option shall terminate on the earlier of such
date of expiration or one year following the date of such death. After the death
of the optionee, his executors, administrators or any person or persons to whom
his option may be transferred by will or by the laws of descent and distribution
shall have the right, at any time prior to such termination, to exercise the
option to the extent the optionee was entitled to exercise such option at the
time of his death.

     If, before the date of the expiration of an option that is subject to
clause (b) of Section 5.1 above, the optionee shall be retired in good standing
from the Company for reasons of age or disability under the then established
rules of the Company, the option shall terminate on the earlier of such date of
expiration or ninety (90) days after the date of such retirement. In the event
of such retirement, the optionee shall have the right prior to the termination
of such option to exercise the option to the extent to which he was entitled to
exercise such option immediately prior to such retirement.

SECTION 6. TERMS OF THE OPTION AGREEMENTS

     Each option agreement shall be in writing and shall contain such terms,
conditions, restrictions, if any, and provisions as the Plan Administrator shall
from time to time deem appropriate. Such provisions or conditions may include,
without limitation, restrictions on transfer, repurchase rights, or such other
provisions as shall be determined by the Plan Administrator; provided, however,
that such additional provisions shall not be inconsistent with any other term or
condition of the Plan and such additional provisions shall not cause any
Incentive Stock Option granted under the Plan to fail to qualify as an incentive
stock option within the meaning of Section 422 of the Code.

     Option agreements need not be identical, but each option agreement by
appropriate language shall include the substance of all of the following
provisions:

          6.1 Expiration of Option.  Notwithstanding any other provision of the
     Plan or of any option agreement, each option shall expire on the date
     specified in the option agreement, which date shall not, in the case of an
     Incentive Stock Option, be later than the tenth anniversary (fifth
     anniversary in the case of a greater-than-ten-percent stockholder) of the
     date on which the option was granted or as specified in Section 5 of this
     Plan.

          6.2 Exercise.  Each option may be exercised, so long as it is valid
     and outstanding, from time to time in part or as a whole, subject to any
     limitations with respect to the number of shares for which the option may
     be exercised at a particular time and to such other conditions as the Plan
     Administrator in its discretion may specify upon granting the option.

          6.3 Purchase Price.  The purchase price per share under each option
     shall be determined by the Plan Administrator at the time the option is
     granted; provided, however, that the option price of any Incentive Stock
     Option shall not, unless otherwise permitted by the Code or other
     applicable law or regulation, be less than the fair market value of the
     Common Stock on the date the option is granted (110% of the fair market
     value in the case of a greater-than-ten-percent stockholder) and the option
     price of any Nonqualified Option shall not be less than 85% of the fair
     market value of the Common Stock on the date the option is granted. For the
     purpose of the Plan the fair market value of the Common Stock shall be the
     closing price per share on the date of grant of the option as reported by a
     nationally recognized stock exchange, or, if the Common Stock is not listed
     on such an exchange, as

<PAGE>   5

     reported by the National Association of Securities Dealers Automated
     Quotation System ("Nasdaq") National Market System or, if the Common Stock
     is not listed on the Nasdaq National Market System, the mean of the bid and
     asked prices per share on the date of grant of the option or, if the Common
     Stock is not traded over-the-counter, the fair market value as determined
     by the Plan Administrator.

          6.4 Transferability of Options.  Options shall not be transferable by
     the optionee otherwise than by will or under the laws of descent and
     distribution, and shall be exercisable, during his lifetime, only by the
     optionee. Notwithstanding the foregoing, the Plan Administrator may, in its
     sole discretion, permit the transfer or assignment of a Nonqualified Option
     by the original optionee for no consideration to: (i) any member of the
     optionee's Immediate Family; (ii) any trust solely for the benefit of
     members of the optionee's Immediate Family; (iii) any partnership whose
     only partners are members of the optionee's Immediate Family; or (iv) any
     limited liability company or corporate entity whose only members or other
     equity owners are members of the optionee's Immediate Family. For purposes
     of this Section 6.4, "Immediate Family" means an optionee's parents,
     spouse, children and grandchildren. Nothing contained in this Section 6.4
     shall be construed to require the Plan Administrator to give its approval
     to any transfer or assignment of any Nonqualified Option or portion
     thereof, and approval to transfer or assign any Nonqualified Option or
     portion thereof does not mean that such approval will be given with respect
     to any other Nonqualified Option or portion thereof. The transferee or
     assignee of any Nonqualified Option shall be subject to all of the terms
     and conditions applicable to such Nonqualified Option immediately prior to
     the transfer or assignment and shall be subject to any conditions
     prescribed by the Plan Administrator with respect to such Nonqualified
     Option. In particular, and without limiting the generality of the
     foregoing, the termination of employment, retirement or death of the
     original optionee shall continue to determine the term and time for
     exercise of such Nonqualified Option for purposes of Sections 5.1 and 5.2
     above.

          6.5 Rights of Optionees.  No optionee shall be deemed for any purpose
     to be the owner of any shares of Common Stock subject to any option unless
     and until the option shall have been exercised pursuant to the terms
     thereof, and the Company shall have issued and delivered certificates
     representing such shares to the optionee.

          6.6 Certain Rights of the Company.  The Plan Administrator may in its
     discretion provide upon the grant of any option hereunder that the Company
     shall have an option to repurchase upon such terms and conditions as
     determined by the Plan Administrator all or any number of shares purchased
     upon exercise of such option or a right of first refusal in connection with
     subsequent transfer of any or all of such shares. The repurchase price per
     share payable by the Company shall be such amount or be determined by such
     formula as is fixed by the Plan Administrator at the time the option for
     the shares subject to repurchase is granted. In the event the Plan
     Administrator shall grant options subject to the Company's repurchase
     option or right of first refusal, the certificates representing the shares
     purchased pursuant to such option shall carry a legend satisfactory to
     counsel for the Company referring to the Company's repurchase option or
     right of first refusal.

          6.7 "Lockup" Agreement.  The Plan Administrator may in its discretion
     specify upon granting an option that upon request of the Company or the
     underwriters managing any underwritten offering of the Company's
     securities, the optionee shall agree in writing that for a period of time
     (not to exceed 180 days) from the effective date of any registration of
     securities of the Company, the optionee will not sell, make any short sale
     of, loan, grant any option for the purchase of, or otherwise dispose of any
     shares issued pursuant to the exercise of such option, without the prior
     written consent of the Company or such underwriters, as the case may be.

SECTION 7. METHOD OF EXERCISE; PAYMENT OF PURCHASE PRICE

     7.1 Method of Exercise.  Any option granted under the Plan may be exercised
by the optionee by delivering to the Company on any business day a written
notice specifying the number of shares of

<PAGE>   6

Common Stock the optionee then desires to purchase and specifying the address to
which the certificates for such shares are to be mailed (the "Notice"),
accompanied by payment for such shares.

     7.2 Payment of Purchase Price.  Payment for the shares of Common Stock
purchased pursuant to the exercise of an option shall be made either by (i) cash
or check equal to the option price for the number of shares specified in the
Notice, or (ii) with the consent of the Plan Administrator, other shares of
Common Stock which (a) either have been owned by the optionee for more than six
(6) months on the date of surrender or were not acquired, directly or
indirectly, from the Company, and (b) have a fair market value on the date of
surrender not greater than the aggregate option price of the shares as to which
such option shall be exercised, (iii) with the consent of the Plan
Administrator, delivery of such documentation as the Plan Administrator and the
broker, if applicable, shall require to effect an exercise of the option and
delivery to the Company of the sale or loan proceeds required to pay the option
price, (iv) with the consent of the Plan Administrator, such other consideration
which is acceptable to the Plan Administrator and which has a fair market value
equal to the option price of such shares, or (v) with the consent of the Plan
Administrator, a combination of (i), (ii), (iii) or (iv). For the purpose of the
preceding sentence, the fair market value per share of Common Stock so delivered
to the Company shall be determined in the manner specified in Section 6.3. As
promptly as practicable after receipt of the Notice and accompanying payment,
the Company shall deliver to the optionee certificates for the number of shares
with respect to which such option has been so exercised, issued in the
optionee's name; provided, however, that such delivery shall be deemed effected
for all purposes when the Company or a stock transfer agent of the Company shall
have deposited such certificates in the United States mail, addressed to the
optionee, at the address specified in the Notice.

SECTION 8. CHANGES IN COMPANY'S CAPITAL STRUCTURE

     8.1 Rights of Company.  The existence of outstanding options shall not
affect in any way the right or power of the Company or its stockholders to make
or authorize, without limitation, any or all adjustments, recapitalizations,
reorganizations or other changes in the Company's capital structure or its
business, or any merger or consolidation of the Company, or any issue of Common
Stock, or any issue of bonds, debentures, preferred or prior preference stock or
other capital stock ahead of or affecting the Common Stock or the rights
thereof, or the dissolution or liquidation of the Company, or any sale or
transfer of all or any part of its assets or business, or any other corporate
act or proceeding, whether of a similar character or otherwise.

     8.2 Recapitalizations, Stock Splits and Dividends.  If the Company shall
effect a subdivision or consolidation of shares or other capital readjustment,
the payment of a stock dividend, or other increase or reduction of the number of
shares of the Common Stock outstanding, in any such case without receiving
compensation therefor in money, services or property, then (i) the number,
class, and price per share of shares of stock subject to outstanding options
hereunder shall be appropriately adjusted in such a manner as to entitle an
optionee to receive upon exercise of an option, for the same aggregate cash
consideration, the same total number and class of shares as he would have
received as a result of the event requiring the adjustment had he exercised his
option in full immediately prior to such event; (ii) the number and class of
shares with respect to which options may be granted under the Plan; and (iii)
the number and class of shares set forth in Sections 3.3 and 4.4, shall be
adjusted by substituting for the total number of shares of Common Stock then
reserved for issuance under the Plan that number and class of shares of stock
that the owner of an equal number of outstanding shares of Common Stock
immediately prior to the event requiring adjustment would own as the result of
such event.

     8.3 Merger without Change of Control.  After a merger of one or more
corporations with or into the Company or after a consolidation of the Company
and one or more corporations in which the stockholders of the Company
immediately prior to such merger or consolidation own after such merger or
consolidation shares representing at least fifty percent (50%) of the voting
power of the Company or the surviving or resulting corporation, as the case may
be, each holder of an outstanding option shall, at no additional cost, be
entitled upon exercise of such option to receive in lieu of the shares of Common
Stock as to which such option was exercisable immediately prior to such event,
the number and class of shares of stock or

<PAGE>   7

other securities, cash or property (including, without limitation, shares of
stock or other securities of another corporation or Common Stock) to which such
holder would have been entitled pursuant to the terms of the agreement of merger
or consolidation if, immediately prior to such merger or consolidation, such
holder had been the holder of record of a number of shares of Common Stock equal
to the number of shares for which such option shall be so exercised.

     8.4 Change of Control.  If the Company is merged with or into or
consolidated with another corporation, other than a merger or consolidation
which would result in the voting securities of the Company outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving
entity) more than fifty percent (50%) of the combined voting power of the voting
securities of the Company or such surviving entity outstanding immediately after
such merger or consolidation; or if the Company is liquidated, or sells or
otherwise disposes of substantially all of its assets to another corporation
while unexercised options remain outstanding under the Plan, then in such event
either:

          (a) subject to the provisions of clause (c) below, after the effective
     date of such merger, consolidation, liquidation, sale or disposition, as
     the case may be, each holder of an outstanding option shall be entitled,
     upon exercise of such option, to receive, in lieu of the shares of Common
     Stock as to which such option was exercisable immediately prior to such
     event, the number and class of shares of stock or other securities, cash or
     property (including, without limitation, shares of stock or other
     securities of another corporation or common stock) to which such holder
     would have been entitled pursuant to the terms of the merger,
     consolidation, liquidation, sale or disposition if, immediately prior to
     such event, such holder had been the holder of a number of shares of Common
     Stock equal to the number of shares as to which such option shall be so
     exercised;

          (b) the Plan Administrator may accelerate the time for exercise of
     some or all unexercised and unexpired options so that from and after a date
     prior to the effective date of such merger, consolidation, liquidation,
     sale or disposition, as the case may be, specified by the Plan
     Administrator such accelerated options shall be exercisable in full; or

          (c) all outstanding options may be canceled by the Plan Administrator
     as of the effective date of any such merger, consolidation, liquidation,
     sale or disposition provided that (x) notice of such cancellation shall be
     given to each holder of an option and (y) each holder of an option shall
     have the right to exercise such option to the extent that the same is then
     exercisable or, if the Plan Administrator shall have accelerated the time
     for exercise of all unexercised and unexpired options, in full during the
     10-day period preceding the effective date of such merger, consolidation,
     liquidation, sale or disposition.

     8.5 Adjustments to Common Stock Subject to Options.  Except as hereinbefore
expressly provided, the issue by the Company of shares of stock of any class, or
securities convertible into shares of stock of any class, for cash or property,
or for labor or services, either upon direct sale or upon the exercise of rights
or warrants to subscribe therefor, or upon conversion of shares or obligations
of the Company convertible into such shares or other securities, shall not
affect, and no adjustment by reason thereof shall be made with respect to, the
number or price of shares of Common Stock then subject to outstanding options.

     8.6 Miscellaneous.  Adjustments under this Section 8 shall be determined by
the Plan Administrator, and such determinations shall be conclusive. No
fractional shares of Common Stock shall be issued under the Plan on account of
any adjustment specified above.

SECTION 9. GENERAL RESTRICTIONS

     9.1 Investment Representations.  The Company may require any person to whom
an option is granted, as a condition of exercising such option, to give written
assurances in substance and form satisfactory to the Company to the effect that
such person is acquiring the Common Stock subject to the option for his own
account for investment and not with any present intention of selling or
otherwise

<PAGE>   8

distributing the same, and to such other effects as the Company deems necessary
or appropriate in order to comply with federal and applicable state securities
laws.

     9.2 Compliance with Securities Laws.  The Company shall not be required to
sell or issue any shares under any option if the issuance of such shares shall
constitute a violation by the optionee or by the Company of any provision of any
law or regulation of any governmental authority. In addition, in connection with
the Securities Act of 1933, as now in effect or hereafter amended (the "Act"),
upon exercise of any option, the Company shall not be required to issue such
shares unless the Plan Administrator has received evidence satisfactory to it to
the effect that the holder of such option will not transfer such shares except
pursuant to a registration statement in effect under such Act or unless an
opinion of counsel satisfactory to the Company has been received by the Company
to the effect that such registration is not required. Any determination in this
connection by the Plan Administrator shall be final, binding and conclusive. In
the event the shares issuable on exercise of an option are not registered under
the Act, the Company may imprint upon any certificate representing shares so
issued the following legend or any other legend which counsel for the Company
considers necessary or advisable to comply with the Act and with applicable
state securities laws:

    The shares of stock represented by this certificate have not been registered
    under the Securities Act of 1933 or under the securities laws of any State
    and may not be pledged, hypothecated, sold or otherwise transferred except
    upon such registration or upon receipt by the Corporation of an opinion of
    counsel satisfactory to the Corporation, in form and substance satisfactory
    to the Corporation, that registration is not required for such sale or
    transfer.

     The Company may, but shall in no event be obligated to, register any
securities covered hereby pursuant to the Act; and in the event any shares are
so registered the Company may remove any legend on certificates representing
such shares. The Company shall not be obligated to take any other affirmative
action in order to cause the exercise of an option or the issuance of shares
pursuant thereto to comply with any law or regulation of any governmental
authority.

     9.3 Employment Obligation.  The granting of any option shall not impose
upon the Company (or any parent or subsidiary of the Company) any obligation to
employ or continue to employ any optionee; and the right of the Company (or any
such parent or subsidiary) to terminate the employment of any officer or other
employee shall not be diminished or affected by reason of the fact that an
option has been granted to him/her.

     9.4 Withholding Tax.  Whenever under the Plan shares of Common Stock are to
be delivered upon exercise of an option, the Company shall be entitled to
require as a condition of delivery that the optionee remit an amount sufficient
to satisfy all federal, state and other governmental withholding tax
requirements related thereto.

SECTION 10. AMENDMENT OR TERMINATION OF THE PLAN

     The Board of Directors may modify, revise or terminate this Plan at any
time and from time to time, except that (i) the class of persons eligible to
receive options and the aggregate number of shares issuable pursuant to this
Plan shall not be changed or increased, other than by operation of Section 8
hereof, without the consent of the stockholders of the Company and (ii) the
provisions of Section 4.4 shall not be amended more than once every six (6)
months, other than to comport with changes in the Code, the Employee Retirement
Income Security Act of 1974, or the rules thereunder.

SECTION 11. NONEXCLUSIVITY OF THE PLAN

     Neither the adoption of the Plan by the Board of Directors nor the
submission of the Plan to the stockholders of the Company for approval shall be
construed as creating any limitations on the power of the Board of Directors to
adopt such other incentive arrangements as it may deem desirable, including,
without limitation, the granting of stock options otherwise than under the Plan,
and such arrangements may be either applicable generally or only in specific
cases.

<PAGE>   9

SECTION 12. EFFECTIVE DATE AND DURATION OF PLAN

     The Plan shall become effective upon its adoption by the Board of
Directors. No option may be granted under the Plan after the tenth anniversary
of the effective date. The Plan shall terminate (i) when the total amount of
Common Stock with respect to which options may be granted shall have been issued
upon the exercise of options or (ii) by action of the Board of Directors
pursuant to Section 10 hereof, whichever shall first occur.

                                * * * * * * * *

<PAGE>   10

     This Appendix constitutes the UK Approved Part of the Charles River
Associates Incorporated 1998 Incentive and Nonqualified Stock Option Plan. The
terms of the UK Approved Part are as follows:

1. INTERPRETATION

     (1) The following words and expressions have the following meanings except
where the context otherwise requires:

          "ACQUISITION PRICE" the price, as determined by the Plan
     Administrator, at which each Share subject to an Option may be acquired on
     the exercise of that Option, which must not be less than the Market Value
     of a Share at the Date of Grant or if the Option relates to unissued
     Shares, its nominal value, if greater.

          The Acquisition Price may be varied under Rule 11 and, if Rule 13 has
     been applied, the "ACQUISITION PRICE" shall be the price for the
     acquisition of a share in the company whose shares are scheme shares
     determined under Rule 13;

          "APPROVAL" approval of the UK Approved Part as a share option scheme
     under Schedule 9 of the ICTA;

          "APPROVED PART" the UK Approved Section of the Plan, in its present
     form, as from time to time amended in accordance with the rules;

          "AUDITORS" the auditors for the time being of the Company whose shares
     are scheme shares;

          "CONTROL" has the same meaning as in Section 840 of the ICTA;

          "DATE OF GRANT" the date on which an Option is granted under Rule 3;

          "ELIGIBLE EMPLOYEE" any person holding Employment who is not precluded
     from participating in the Scheme by paragraph 8 of Schedule 9 of the ICTA;

          "EMPLOYMENT" employment as an employee or director of the Company or
     any Affiliate who is resident in the United Kingdom and who is required to
     devote substantially the whole of his working time to the performance of
     his duties;

          "GRANT PERIOD" the period of 42 days commencing on the day after any
     of the following:

             (a) the date on which the Company releases its interim results or
        its final results for any financial period; or

             (b) the date on which listing particulars or a document containing
        equivalent information relating to Shares is issued; or

             (c) the date on which Approval is given;

     provided that no Option may be granted until Approval has been obtained.

          "GROUP" the Company and its Subsidiaries which are under the Control
     of the Company;

          "ICTA" Income and Corporation Taxes Act 1988;

          "ISSUE OR REORGANISATION" any variation in the capital of the Company
     (or any other company whose shares are scheme shares following an exchange
     of options pursuant to Rule 13) arising from or in connection with a
     capitalisation issue, an offer to the holders of Shares by way of rights, a
     subdivision, consolidation, reduction or other variation of share capital;

          "MARKET VALUE" means an amount equal to the market value of a Share
     determined in accordance with Part VIII of the Taxation of Chargeable Gains
     Act 1992 agreed in advance for the purposes of the Scheme with the Shares
     Valuation Division of the Inland Revenue;

<PAGE>   11

          "OPTION" means a right to acquire Shares under the UK Approved Part;

          "OTHER EXECUTIVE OPTION SCHEME" any Other Option Scheme the grant of
     any option under which is in practice substantially limited to persons of
     executive status;

          "OTHER OPTION SCHEME" any employee share option scheme adopted by the
     Company in the United Kingdom, other than the Plan, providing for the issue
     of Shares;

          "PARTICIPATING COMPANY" any company within the Group to which the Plan
     Administrator from time to time extends the Scheme;

          "REMUNERATION" at any particular time, an Eligible Employee's relevant
     emoluments for the current or preceding year of assessment (whichever of
     those years gives the greater amount) or, if there were no relevant
     emoluments for the preceding year of assessment, his relevant emoluments
     for the period of twelve months beginning with the first day during the
     current year of assessment in respect of which there are relevant
     emoluments and "relevant emoluments" has the meaning ascribed to it in
     paragraph 28(4) of Schedule 9 of the ICTA;

          "SHARE" a share of common stock of the Company or, if Rule 13 has been
     applied, the company whose shares are scheme shares which satisfies the
     conditions of paragraphs 10 to 14 of Schedule 9 of the ICTA;

          "SUBSIDIARY" a company which is a subsidiary of the Company within the
     meaning of Section 736 of the Companies Act 1985;

     (2) Other words or expressions, so far as not inconsistent with the
context, shall have the same meanings as in Schedule 9 of the ICTA or the rules
of the Plan.

     (3) Words importing the singular shall include the plural and vice versa
and words importing the masculine shall include the feminine.

     (4) Any reference, express or implied, to an enactment includes references
to:

          (a) that enactment as amended, extended or applied by or under any
     other enactment; and

          (b) any enactment which that enactment re-enacts (with or without
     modification).

     "UK APPROVED PART" the UK Approved Section of the Plan, in its present
     form, as from time to time amended in accordance with the rules.

2. ELIGIBILITY

     No person is entitled as of right to participate in the UK Approved Part.
The Plan Administrator may decide from time to time which Eligible Employee or
Eligible Employees may participate and the extent of the participation.

3. GRANT OF OPTIONS

     (1) The Plan Administrator may adopt any procedure for granting Options.
Options may be granted by the Plan Administrator. The form for the time being of
any Option certificate or other document shall be determined by the Plan
Administrator subject to the approval of the Inland Revenue.

     (2) Options shall be granted by deed. A single deed of grant may be
executed in favour of any number of persons.

     (3) The Date of Grant of an Option shall be the day on which the deed
granting the Option is executed, or such later date as may be approved in the
deed.

     (4) A participant who is granted an Option by deed may, with the consent of
the Plan Administrator, renounce the Option, in whole or in part, within 30 days
of the Date of Grant and, to the extent renounced, shall be treated as if it had
never been granted.

<PAGE>   12

     (5) If Shares are listed or dealt in on the Unlisted Securities Market of
the London Stock Exchange the Date of Grant must be chosen so that each dealing
day used to determine the Acquisition Price lies within a Grant Period. However,
Options may be granted at any other time when the Plan Administrator considers
that there are exceptional circumstances justifying the grant of Options.

     (6) An Option certificate or deed of grant shall be sent to the Optionee as
soon as practicable after an Option has been granted.

     (7) An Option shall constitute a contract between the Company and the
Optionee incorporating the provisions of the UK Approved Part and the Plan so
far as relevant.

     (8) An Option shall not be granted to an Eligible Employee if he is bound
to retire in accordance with the terms of his contract of employment within two
years of the Date of Grant.

4. PERFORMANCE REQUIREMENTS

     (1) The Plan Administrator may grant an Option to an Eligible Employee
subject to such objective additional terms and conditions as they consider
appropriate.

     (2) The Plan Administrator may subsequently alter or waive any additional
terms and conditions imposed under sub-rule (1) provided that any alteration to
a term or condition relating to performance must be such that the altered term
or condition reflects a fairer measure of the performance required and is no
more difficult to satisfy than the term or condition at the Date of Grant.

     (3) The circumstances in which the Plan Administrator may alter or waive
the additional terms and conditions imposed shall be specified in the letter of
invitation (if the invitation procedure is used) or in the letter enclosing the
option certificate or in the deed of grant.

     (4) The Plan Administrator must act fairly and reasonably in imposing,
altering or waiving any terms and conditions and no material terms and
conditions may be imposed or subsequently altered or waived without the prior
approval of the Board of Inland Revenue.

     (5) Any additional terms and conditions to which an Option is subject under
sub-rule 4(1) shall be deemed to be waived in any of the circumstances specified
in Rules 8(1)(b), other than retirement at or after any age at which he is bound
to retire in accordance with the terms of his contract of employment, 8(1)(c),
13 and 14.

5. PROHIBITION ON ASSIGNMENT

     (1) No Option granted under the Scheme may be transferred, assigned,
charged or otherwise alienated (without prejudice to any right of a person's
legal personal representatives to exercise the Option following death).

     (2) If an Optionee enters into a composition with his creditors in
satisfaction of his debts or a bankruptcy order is made against him his Option
will lapse.

6. LIMIT ON SHARES

     The total number of Shares which may be issued under the Plan, including
the UK Approved Part, shall not exceed the number set forth in the Plan. In the
event of an Issue or Reorganisation this number of Shares may be adjusted in
such manner as the Plan Administrator decides provided that the adjustment will
not have effect unless the Auditors certify in writing that the adjustment is in
their opinion fair and reasonable.

<PAGE>   13

7. EXERCISE OF OPTIONS

     (1) Save as provided in Rules 8, 9, 10, 13 and 14, an Option shall be
capable of being exercised in full at any time following the earliest of:

          (a) the third anniversary of the Date of Grant;

          (b) the Optionee's death or ceasing to be in Employment by reason of
     retirement at any age at which the Optionee is bound to retire in
     accordance with the terms of his contract of employment, redundancy, injury
     or disability;

          (c) the Optionee ceasing to be in Employment by reason of the
     Participating Company by which he is employed ceasing to be under the
     Control of the Company or by reason of the transfer or sale of the
     undertaking or part of the undertaking in which he is employed to a person
     who is not under the Control of the Company;

          (d) the occurrence of the circumstances permitting the exercise of
     Options specified in Rule 13 or 14.

     (2) If an Option is subject to additional terms and conditions under Rule
4(2) it may only be exercised in accordance with those terms and conditions.

     (3) An Optionee shall not be treated for the purposes of Rule 7, 8 or 9 as
ceasing to be in Employment until such time as he is no longer a director or
employee of any company within the Group and a female Optionee who ceases
Employment by reason of pregnancy or confinement and who is entitled to exercise
and subsequently exercises her statutory right (or any corresponding contractual
right) to return to work before exercising an Option shall be treated for those
purposes as not ceasing to be in Employment.

     (4) An Option may not be exercised by an Optionee at any time when he is
ineligible to participate in the UK Approved Part by virtue of paragraph 8 of
Schedule 9 of the ICTA.

8. LAPSE OF OPTION

     (1) Unless provided otherwise elsewhere in the Rules, an Option shall lapse
to the extent that it has not been exercised (whether or not it became
exercisable) by the earliest of:

          (a) the tenth anniversary of the Date of Grant;

          (b) the expiry of 90 days from the date on which the Optionee ceases
     to be in Employment by reason of retirement at any age at which the
     Optionee is bound to retire in accordance with the terms of his contract of
     employment, redundancy, injury or disability, or the date on which the
     Optionee ceases to be in Employment by reason of the Participating Company
     by which he is employed ceasing to be under the Control of the Company or
     the transfer or sale of the undertaking or part of the undertaking in which
     he is employed to a person who is not under the Control of the Company;

          (c) the expiry of the period referred to in Rule 13;

          (d) the expiry of the period referred to in Rule 14;

          (e) the date on which:

             (i) the Optionee gives or is given notice to leave Employment if he
        subsequently ceases to be in Employment (and for the avoidance of doubt
        any purported exercise of the Option during the period of notice shall
        be of no effect); or

             (ii) the Optionee ceases to be in Employment without any notice
        having been given in any circumstances other than death and those
        referred to in sub-paragraphs (b) and (c) of this paragraph unless
        (being female) she is entitled to exercise and subsequently does
        exercise the statutory right (or any corresponding contractual right) to
        resume Employment after an absence due to pregnancy or confinement.

<PAGE>   14

     (2) If an Optionee dies at any time when his Option is outstanding whether
or not it is then capable of being exercised, the Option shall be and remain
capable of exercise until the expiry of 90 days from the date of his death but
shall lapse earlier in the circumstances specified in Rule 13 or Rule 14.

     (3) An Option shall not lapse by virtue of this Rule if the occasion for
lapse falls in a period when the Option is capable of being exercised under Rule
13 but the Option shall lapse on the expiry of that period or, if earlier, one
year after the date of the Optionee's death.

9. CESSATION OF EMPLOYMENT -- SPECIAL CIRCUMSTANCES

     (1) If an Optionee ceases to be in Employment, whether or not within the
period specified in sub-rule 7(1)(a), in circumstances in which his Option is
not exercisable under Rule 7 or would lapse immediately under Rule 8 the Plan
Administrator, acting fairly and reasonably, may in its discretion permit his
Option to be exercisable in whole or in part during such period (but not later
than one year after his death) and on such other terms as they may decide.

     (2) If an Option would lapse at the end of any period specified in Rule 8
following the cessation of the Optionee's Employment the Plan Administrator may
defer the lapse of his Option until the end of such longer period as it may
determine, acting fairly and reasonably, but not later than one year after his
death and not exceeding a period which expires three years and six months after
the Date of Grant or, if longer, three years and six months after the last
occasion on which the Optionee exercised an option in circumstances qualifying
for relief from income tax under Section 185 of the ICTA.

     (3) If an Optionee ceases to be in Employment but continues to provide
services to the Group on a part-time basis as an employee or a director or on a
self-employed basis the Plan Administrator may determine acting fairly and
reasonably that his Option shall neither become exercisable nor lapse by virtue
of such cessation and that Rules 8 to 10 shall apply when he subsequently ceases
to provide services to the Group, or in such other circumstances as the Plan
Administrator may determine, acting fairly and reasonably, with such
modifications as are necessary.

10. MANNER OF EXERCISE AND ISSUE OR TRANSFER OF SHARES

     (1) An Option may be exercised by the Optionee giving notice of exercise in
a form approved by the Plan Administrator accompanied by the relevant option
certificate or deed of grant and payment of the total Acquisition Price of the
Shares in respect of which the Option is exercised.

     (2) The Company shall allot or procure the transfer of the Shares in
respect of which the Option has been exercised within 30 days of the date of
exercise.

     (3) Shares issued under the UK Approved Part will rank pari passu in all
respects with issued Shares of the same class. However, they will not be
entitled to any rights attaching to Shares by reference to a record date prior
to the date of exercise of the Option.

     (4) An Option may be exercised in whole or in part and, in the event of an
Option being exercised in part the Plan Administrator may call in or cancel any
outstanding option certificate or deed of grant and furnish the Optionee with
details of the date on which the Option was last exercised and the number of
Shares outstanding under the Option. The Directors may determine, acting fairly
and reasonably, that the Option may only be exercised in respect of a reasonable
minimum number of Shares and/or in respect of a multiple of any round number of
Shares, or in respect of the balance of Shares outstanding in the Option.

     (5) The allotment or transfer of Shares under the Plan is subject to
obtaining any approval or consent required under any applicable regulations or
enactment.

<PAGE>   15

11. ISSUE OR REORGANISATION

     (1) In the event of any Issue or Reorganisation:

          (a) the number of Shares comprised in an Option; and/or

          (b) the Acquisition Price under an Option

may be adjusted in such manner as the Plan Administrator decides subject to the
prior approval of the Inland Revenue and the written concurrence of the Auditors
that in their opinion the adjustment is fair and reasonable.

     (2) Following an adjustment under paragraph (1) above, Shares must continue
to comply with paragraphs 10 to 14 of Schedule 9 of the ICTA.

     (3) If an Option relates to unissued Shares an adjustment under paragraph
(1) above may reduce or further reduce the Acquisition Price below the nominal
value of a Share if:

          (a) a part of the reserves of the Company equal to the difference
     between the adjusted Acquisition Price and the nominal value of the Shares
     concerned ("Relevant Amount") may be capitalised if the Option is exercised
     so as to pay up the Relevant Amount; and

          (b) the Company has sufficient reserves available.

     (4) The Plan Administrator may notify Optionees of any adjustments made
under this Rule 11 and may call in, cancel, endorse, issue or reissue any option
certificate or deed of grant following an adjustment.

12. TAKEOVER AND RECONSTRUCTION

     (1) If:

          (a) a general offer is made to acquire the whole of the issued
     ordinary share capital of the Company (or such part thereof as is not at
     the time owned by the offeror or any company controlled by the offeror
     and/or persons acting in concert with the offeror) and after the
     announcement of the general offer the offeror (and any such companies
     and/or persons) acquires Control of the Company, or

          (b) a general offer is made to acquire the whole of the issued
     ordinary share capital of the Company (or such part thereof as aforesaid)
     by any person who (together with any company controlled by such person
     and/or persons acting in concert with him) has Control of the Company,

a participant may, subject to the provisions of Rule 7, be entitled to exercise
his Option at any time during the period of six months following, in the case of
an offer within paragraph (a) above, the date of the acquisition of Control and,
in the case of an offer within paragraph (b) above, the date on which the offer
is made or, if the offer was conditional, the later date on which the offer
becomes unconditional.

     (2) The Company shall use its best endeavours to procure that if a
participant is allotted Shares pursuant to the exercise of Options in accordance
with Rule 10(1) then if such Shares were not the subject of the said general
offer the offeror shall make an offer to acquire from the participant his Shares
upon the same terms as Shares of the same class were acquired under the general
offer.

13. EXCHANGE OF OPTIONS

     If any company (the "acquiring company") obtains Control of the Company as
a result of making:

          (i) a general offer to acquire the whole of the issued share capital
     of the Company which is made on a condition such that if it is satisfied
     the person making the offer will have Control of the Company, or

<PAGE>   16

          (ii) a general offer to acquire all the shares in the Company which
     are of the same class as the scheme shares,

any participant may at any time within the appropriate period, by agreement with
the acquiring company, release his Option ("old rights") in consideration of the
grant to him of rights ("new rights") which are equivalent to his Option but
relate to shares in a different company (whether the acquiring company itself or
some other company falling within paragraph 10(b) or (c) of Schedule 9 of the
ICTA). "The appropriate period" and "equivalent" have the same meaning as in
paragraph 15 of Schedule 9 of the ICTA and accordingly the new rights shall not
be regarded for the purpose of the Scheme as equivalent to the old rights
unless:

          (a) the shares to which they relate satisfy the conditions specified,
     in relation to scheme shares, in paragraphs 10 to 14 of Schedule 9 of the
     ICTA; and

          (b) the new rights will be exercisable in the same manner as the old
     rights and subject to the provisions of the Scheme as it had effect
     immediately before the release of the old rights; and

          (c) the total Market Value, immediately before the release, of the
     shares which were subject to the participant's old rights is equal to the
     total market value, immediately after the grant of the shares in respect of
     which the new rights are granted to the participant; and

          (d) the total amount payable by the participant for the acquisition of
     shares in pursuance of the new rights is equal to the total amount that
     would have been payable for the acquisition of shares in pursuance of the
     old rights.

The new rights shall for the purposes of the UK Approved Part be treated as
having been granted at the time when the old rights were granted and references
to Shares shall, in relation to the new rights, be taken as references to the
shares of the company whose shares are scheme shares. References to the Company
shall be taken to be references to the company whose shares are scheme shares in
Rules 6, 7, 8, 9, 10, 11, 12(3), and 12(4).

14. VOLUNTARY WINDING UP

     If a resolution for a shareholder's voluntary winding up of the Company is
passed, an Optionee may exercise his Option, subject to Rule 8, within three
months of the date of the resolution.

15. AMENDMENT

     (1) Subject to paragraph (2) below the Plan Administrator may by resolution
at any time amend the rules of the UK Approved Part in any respect except that
any amendment made when the UK Approved Part is approved under Schedule 9 of the
ICTA shall not have effect without the prior approval of the Inland Revenue.

     (2) Subject to paragraph (4) below, no amendment to the UK Approved Part to
the advantage of Optionees or Eligible Employees may be made:

          (a) to the number of Shares specified in Rule 6 and the provisions for
     adjustment of that number (except as provided in Rule 6);

          (b) to the definitions of "Acquisition Price", "Eligible Employee",
     "Employment", "Grant Period", "Group Remuneration" and "Issue or
     Reorganisation";

          (c) which would alter to the advantage of Eligible Employees or
     Optionees, any of the provisions of Rules 4, 5, 6, 7, 8, 9, 11(4), 11(6),
     12, 13, paragraph (2) of this Rule or to the Schedules

without the prior approval of a majority of the stockholders of the Company
present at a meeting of stockholders.

     (3) No amendment shall be made under paragraph (1) which would abrogate or
materially affect adversely the subsisting rights of an Optionee unless it is
made with his written consent or by a resolution

<PAGE>   17

passed as if the Options constituted a separate class of share capital and the
provisions of the Articles of Organisation of the Company relating to class
meetings applied to that class mutatis mutandis.

     (4) Paragraph (2) shall not apply to any amendment which:

          (a) is confined to Options which do not involve the issue of new
     Shares (including the eligibility requirements and the terms of such
     Options insofar as they do not involve the issue of new Shares); or

          (b) is not so confined and affects the limit in Rule 7(3) provided
     that the Plan Administrator is reasonably satisfied that the purpose or
     effect of the amendment is substantially to comply with any current
     published guidelines issued by institutional investors; or

          (c) is not so confined and:

             (i) is necessary or desirable in order to obtain or maintain Inland
        Revenue approval of the Approved Part under Schedule 9 of the ICTA or
        any other enactment, or to comply with or take account of the provisions
        of any proposed or existing legislation or of any Inland Revenue
        practice or concession, or to obtain or maintain favourable taxation
        treatment of the Company, any Subsidiary or any Optionee; and

             (ii) does not affect the basic principles of the Approved Part.

16. DURATION AND TERMINATION

     No Options may be granted under the Approved Part more than ten years after
the date of adoption of the Approved Part by the Company. The Plan Administrator
may at any time terminate the Approved Part and no further Options will be
granted after that date, but Options granted before that date will continue to
be valid and exercisable in accordance with these Rules.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]